SCHEMBL3952425

SCHEMBL3952425

CC(=O)Oc1ccc2c(=O)c(-c3ccc(F)cc3)c(C)oc2c1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.80
KDM4E B2RXH2 6/20 0.80
ALDH1A1 P00352 9/20 0.62
KMT2A Q03164 4/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
MEN1 O00255 2/20 0.62
LMNA P02545 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
MAPK1 P28482 1/20 0.62
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
FPR1 P21462 4/20 0.57
HPGD P15428 1/20 0.55
GAA P10253 3/20 0.54
GLA P06280 1/20 0.54
THRB P10828 1/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6506553 0.94 MAPT (0.86) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL13692850 0.90 MAPT (0.80) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL4683758 0.89 KDM4E (1.00) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL12940400 0.83 MAPT (0.57) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL12941612 0.82 ALDH1A1 (0.69) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL16120877 0.80 KDM4E (0.68) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL2181512 0.80 MAPT (0.61) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL12722331 0.79 ALDH1A1 (0.77) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL27698748 0.79 KDM4E (0.56) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2
SCHEMBL2184783 0.78 KDM4E (0.62) MAPTKDM4EALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2277595-A2 Compounds for immunopotentiation Novartis Vaccines and Diagnostics, Inc. (US) 2011-01-26 EP disclosed
US-20100226931-A1 Compounds for immunopotentiation NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-09-09 US disclosed
US-20100226931-A1 Compounds for immunopotentiation NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2010-09-09 US disclosed
WO-2009026658-A1 PPAR AGONISTS THE UNIVERSITY OF SYDNEY (AU) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226931-A1 Compounds for immunopotentiation LY96, ICOS, PDCD1 MAPT 3668/4885KDM4E 558/4885ALDH1A1 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.